Despite COVID-19, we are operating at full capacity and all project work is operating as usual.

Clinically predictive preclinical efficacy testing services at your disposal



APRIL 30, 2020

Supporting the research related to COVID-19

In severe cases of SARS-CoV-2 infections, the immune system has been hyper-activated, triggering a cytokine release storm (CRS). CRS is body’s excessive immunological response against infection that may ultimately lead to organ failure. Cytokine storms are a common complication of Covid-19 and can also occur after cancer immunotherapy treatment. 

When an individual gets infected by SARS-CoV-2, their immune system starts producing antibodies against viral antigens. Therefore, SARS-CoV-2 infection can be detected by measuring these antibodies in the blood of an individual, possibly also after the individual has cured from the disease.

Pharmatest can measure the levels of multiple cytokines/key inflammation markers that are indicative of pathologic inflammatory response and also SARS-CoV-2 reactive IgG class antibodies from plasma and serum samples.

Mouse models for coronavirus research are available upon request.

More information on cytokine storm and cytokine markers:

The Lancet: COVID-19: consider cytokine storm syndromes and immunosuppression. https://doi.org/10.1016/ S0140-6736(20)30628-0

Nature: In the eye of the COVID-19 cytokine storm.

cytokine_measurements_Pharmatest.jpg